SomnoMed 将来の成長

Future 基準チェック /46

SomnoMed利益と収益がそれぞれ年間76.6%と8.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に11% 76.9%なると予測されています。

主要情報

76.6%

収益成長率

76.91%

EPS成長率

Medical Equipment 収益成長	17.6%
収益成長率	8.7%
将来の株主資本利益率	10.95%
アナリストカバレッジ	Low
最終更新日	03 Oct 2025

今後の成長に関する最新情報

Recent updates

SomnoMed Limited's (ASX:SOM) 29% Dip In Price Shows Sentiment Is Matching Revenues

Apr 25

Further Upside For SomnoMed Limited (ASX:SOM) Shares Could Introduce Price Risks After 27% Bounce

Jan 22

SomnoMed Limited (ASX:SOM) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 02

Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet

Oct 16

SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

Jul 15

SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

May 31

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Apr 15

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

Nov 18

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Sep 27

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

May 10

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Oct 26

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

May 12

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

Mar 02

Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Feb 01

Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Dec 28

Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Dec 01

Analysts Just Published A Bright New Outlook For SomnoMed Limited's (ASX:SOM)

Jul 28

SomnoMed Limited (ASX:SOM) Insiders Increased Their Holdings

Jul 14

業績と収益の成長予測

ASX:SOM - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2028	145	7	7	14	3
6/30/2027	133	5	6	11	3
6/30/2026	122	2	-1	8	3
6/30/2025	111	-3	4	8	N/A
3/31/2025	106	-5	1	5	N/A
12/31/2024	100	-6	-2	2	N/A
9/30/2024	96	-9	-7	-2	N/A
6/30/2024	92	-12	-11	-6	N/A
3/31/2024	90	-11	-10	-6	N/A
12/31/2023	89	-11	-10	-5	N/A
9/30/2023	86	-9	-10	-4	N/A
6/30/2023	84	-8	-10	-4	N/A
3/31/2023	81	-7	-11	-3	N/A
12/31/2022	79	-5	-11	-2	N/A
9/30/2022	76	-5	-9	0	N/A
6/30/2022	73	-4	-7	2	N/A
3/31/2022	69	-5	-6	1	N/A
12/31/2021	66	-5	-6	-1	N/A
9/30/2021	64	-3	-4	1	N/A
6/30/2021	63	-1	-1	3	N/A
3/31/2021	59	-1	2	5	N/A
12/31/2020	55	-1	5	7	N/A
9/30/2020	56	-1	4	6	N/A
6/30/2020	57	0	3	5	N/A
3/31/2020	60	0	0	2	N/A
12/31/2019	63	1	-4	-1	N/A
9/30/2019	61	0	-6	-4	N/A
6/30/2019	59	0	-8	-7	N/A
3/31/2019	58	2	N/A	N/A	N/A
12/31/2018	56	3	N/A	-7	N/A
9/30/2018	54	3	N/A	-8	N/A
6/30/2018	52	2	N/A	-9	N/A
3/31/2018	51	-1	N/A	N/A	N/A
12/31/2017	50	-4	N/A	-8	N/A
9/30/2017	50	-4	N/A	-5	N/A
6/30/2017	49	-3	N/A	-3	N/A
3/31/2017	48	-2	N/A	-1	N/A
12/31/2016	47	-1	N/A	0	N/A
9/30/2016	45	0	N/A	1	N/A
6/30/2016	44	0	N/A	2	N/A
3/31/2016	42	0	N/A	2	N/A
12/31/2015	39	1	N/A	1	N/A
9/30/2015	37	1	N/A	0	N/A
6/30/2015	34	1	N/A	0	N/A
3/31/2015	34	1	N/A	0	N/A
12/31/2014	35	1	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SOMは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 3.1% ) よりも高い成長率であると考えられます。

収益対市場: SOM今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: SOM今後 3 年以内に収益を上げることが予想されます。

収益対市場: SOMの収益 ( 8.7% ) Australian市場 ( 5.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: SOMの収益 ( 8.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SOMの自己資本利益率は、3年後には低くなると予測されています ( 11 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/10/03 06:52
終値	2025/10/03 00:00
収益	2025/06/30
年間収益	2025/06/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

SomnoMed Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。5

アナリスト	機関
Iain Wilkie	Morgans Financial Limited
Peter Meichelboeck	Select Equities Pty Ltd
Dennis Hulme	Taylor Collison Limited

SomnoMed 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Somnomed Limited Reiterates Earnings Guidance for the Fy2025

SomnoMed Limited Revises Earnings Guidance for Fiscal Year 2025

Price target increased by 25% to AU$2.07

Price target decreased by 12% to AU$1.88

Consensus forecasts updated

Consensus forecasts updated

Recent updates

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

SomnoMed Limited to Report Fiscal Year 2025 Results on Aug 28, 2025

New minor risk - Share price stability

SomnoMed Limited's (ASX:SOM) 29% Dip In Price Shows Sentiment Is Matching Revenues

Somnomed Limited Reiterates Earnings Guidance for the Fy2025

SomnoMed Limited to Report First Half, 2025 Results on Feb 28, 2025

Further Upside For SomnoMed Limited (ASX:SOM) Shares Could Introduce Price Risks After 27% Bounce

SomnoMed Limited Appoints Andrew Price as Director

Chairman of the Board recently bought AU$295k worth of stock

SomnoMed Limited (ASX:SOM) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

New major risk - Share price stability

SomnoMed Limited Revises Earnings Guidance for Fiscal Year 2025

SomnoMed Limited, Annual General Meeting, Nov 27, 2024

Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet

SomnoMed Limited Announces Board Changes

Full year 2024 earnings released: AU$0.10 loss per share (vs AU$0.10 loss in FY 2023)

Full year 2024 earnings released: AU$0.10 loss per share (vs AU$0.10 loss in FY 2023)

SomnoMed Limited to Report Fiscal Year 2024 Results on Aug 28, 2024

SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

New major risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New major risk - Share price stability

No independent directors

SomnoMed Limited has filed a Follow-on Equity Offering in the amount of AUD 22.6 million.

Price target increased by 25% to AU$2.07

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

SomnoMed Limited to Report First Half, 2024 Results on Feb 28, 2024

Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

New major risk - Revenue and earnings growth

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.499249 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Full year 2023 earnings: Revenues in line with analyst expectations

New minor risk - Financial data availability

SomnoMed Limited to Report Q4, 2023 Results on Aug 24, 2023

Somnomed Limited Announces Executive Changes

Is SomnoMed (ASX:SOM) Using Too Much Debt?

Price target decreased by 12% to AU$1.88

First half 2023 earnings released: AU$0.047 loss per share (vs AU$0.038 loss in 1H 2022)

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 25, 2022

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Consensus forecasts updated

Full year 2022 earnings: EPS misses analyst expectations

SomnoMed Limited Provides Earnings Guidance for the Year 2023

Price target decreased to AU$2.16

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

No independent directors

Global CEO recently sold AU$81k worth of stock

SomnoMed Introduces Rest Assure

First half 2022 earnings: EPS and revenues miss analyst expectations

SomnoMed Limited Provides Earnings Guidance for the Second Half of Fiscal Year 2022 and Reaffirms Earnings Guidance for the Fiscal Year 2022

SomnoMed Limited to Report First Half, 2022 Results on Feb 22, 2022

SomnoMed Limited Announces World First Technology Enabled Oral Appliance

Chairman of the Board recently bought AU$499k worth of stock

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Full year 2021 earnings released: AU$0.014 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Full year 2021 earnings released: AU$1.38 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

First half 2021 earnings released: EPS AU$0.008 (vs AU$0.014 in 1H 2020)